Inspira Technologies OXY B.H.N. Ltd.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) develops, manufactures and markets innovative respiratory support and diagnostic technologies as alternatives to invasive mechanical ventilation for patients with acute respiratory failure; its core products include the U.S. FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass procedures and ECMO internationally, the next-generation INSPIRA ART500 designed to oxygenate blood while patients remain awake and spontaneously breathing, the HYLA real-time continuous non-invasive blood sensor for monitoring key parameters like oxygen saturation and alerting clinicians to condition changes, and the ALICE cardio-pulmonary bypass device. Founded in 2018 and headquartered in Ra'anana, Israel, the company targets the $19 billion mechanical ventilation market serving approximately 20 million annual intensive care patients globally, with operations focused on North America, Europe, Asia Pacific, Latin America, the Middle East and Africa through distribution agreements and OEM partnerships including an exclusive manufacturing deal with Terumo Cardiovascular. Recent developments encompass a October 2025 strategic alliance with Bites Learning Ltd. to embed AI-powered training, simulations and analytics into future INSPIRA ART100 and HYLA systems for enhanced hospital onboarding and compliance; a December 2025 expansion of blood laboratory capabilities to accelerate next-generation sensor and analysis technologies; activation of a U.S. consulting firm in July 2025 to pursue high-value transactions and commercial growth following major purchase orders totaling $49 million from African health authorities; and ongoing clinical integrations in top U.S. hospitals alongside a growing patent portfolio featuring granted U.S. patents for VORTX oxygenation, dual lumen cannula and initiation modules.
Company News
Correction: QTREX Establishes Cryogenic Interconnect Capacity, More Than Four Times the Highest Publicly Disclosed Industry Benchmark
QTREX to Unveil Ultra-High-Density Interconnect Architecture Supporting 17,280 Coaxial Lines per Cryogenic Stage at IEEE Quantum Week 2026
Inspira Technologies OXY B.H.N. (NASDAQ:IINN) Shares Up 24.8% – Time to Buy?
QTREX Announces Pricing of a $10 Million Registered Direct Offering of Ordinary Shares
QTREX's Patent-Pending Technology Achieves First Direct Conversion of 3D-Printed Insulation into Graphene-Like Carbon to Protect Quantum Processors
Inspira Technologies OXY B.H.N. (IINN) to Post Earnings on Thursday
QTREX Proprietary Quantum Interconnect Platform Exceeds Performance Requirements Established by Strategic Partners
QTREX Launches Quantum Interconnect Research Program with Commercialization Rights to Project-Generated IP
QTREX Appoints Dr. Shlomit Chappel-Ram, Veteran AME R&D Executive, as Independent Director
QTREX Establishes U.S. Subsidiary to Advance Federal Government Contracting
QTREX Announces Operational AME System at U.S. Government Lab with a Quantum Computing Program focused on National Security
QTREX Engineers Conductivity Itself to Address Quantum Computing's Cryogenic Heat-Load Barrier
QTREX Awarded Government Grant to Advance the World's First Native RF Dielectric Material for Quantum Computing
QTREX to Showcase Functional AME-Based Monolithic Connectivity Components for Quantum Computing Systems at Quantum.Tech World 2026 in Boston
QTREX Secures Purchase Order from a U.S.-based Fortune 500 company for an AME System and Related Materials
QTREX in Advanced Discussions with Top-Five Global Quantum Computing Company Regarding Strategic Collaboration
Inspira Technologies to Begin Trading as QTREX Quantum Under Nasdaq Ticker "QTEX" on May 20, 2026, Following Strategic Focus on AME and Quantum Connectivity
NYU Langone Issues $580,000 Purchase Order for Inspira's FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation
Inspira Technologies CEO Issues Letter to Shareholders on Strategic Direction and Value Creation Plan
Inspira Technologies CEO Issues Letter to Shareholders on Strategic Direction and Value Creation Plan